Tranexamic acid plus misoprostol

PreclinicalSmall molecule

Tranexamic acid plus misoprostol is one of 2 small molecule programs targeting Vaginal Delivery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vaginal DeliveryCompleted

Vaginal DeliveryPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Vaginal Delivery

#DrugCompanyPhaseTrials

Lignocaine

UUniversity of Malaya

Preclinical

1 2

Tranexamic acid plus misoprostol

AAswan University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaginal Delivery1 trial

Carbetocin Versus Oral Tranexamic Acid Plus, Buccal Misoprostol on Blood Loss After Vaginal Delivery

Completed·—·N/A·NCT03708497·360 enrolled

Cesarean Delivery1 trial

Tranexamic Acid Plus Buccal Misoprostol on Blood Loss During and After Cesarean Delivery

Completed·—·N/A·NCT03710304·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tranexamic acid plus misoprostol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tranexamic acid plus misoprostol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tranexamic acid plus misoprostol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aswan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAswan University Hospital

Tranexamic acid plus misoprostol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vaginal Delivery1 trial

Cesarean Delivery1 trial

References

Drug Info

Quick Facts

Related News